TY - JOUR
T1 - Ribosomal Protein S27-Like in Colorectal Cancer
T2 - A Candidate for Predicting Prognoses
AU - Huang, Chi Jung
AU - Yang, Shung Haur
AU - Lee, Chia Long
AU - Cheng, Yu Che
AU - Tai, Szu Yun
AU - Chien, Chih Cheng
N1 - Funding Information:
The authors would like to thank Drs. Jen-Kou Lin and Shih-Ching Chang (both from Department of Surgery, Taipei-Veterans General Hospital) who informed us the clinical data of some patients and Dr. Yih-Yiing Wu for his superior support in pathology. We also thank National RNAi Core Facility at the Institute of Molecular Biology/Genomic Research Center, Academia Sinica to provide RNAi reagents which were supported by the National Research Program for Genomic Medicine Grants of NSC (NSC 97–3112-B-001–016).
PY - 2013/6/24
Y1 - 2013/6/24
N2 - Background:The development and progression of colorectal cancer (CRC) involve a complex process of multiple genetic changes. Tumor suppressor p53 is capable of determining the fate of CRC cells. However, the role of a p53-inducible modulator, ribosomal protein S27-like (RPS27L), in CRC is unknown.Methods:Here, the differential expression of RPS27L was examined in the feces and colonic tissues of CRC patients, to explore its possible correlation with patient survival and to investigate the cellular mechanisms underlying their clinical outcomes. Eighty intermediate-stage CRC patients (42 at stage II and 38 at stage III) were divided into two groups according to their fecal RPS27L mRNA levels. The survival probabilities of the groups were estimated using the Kaplan-Meier method. The RPS27L protein in the colonic tissues of stage III patients with different prognoses was further examined immunohistochemically. RPS27L expression in LoVo cells was manipulated to examine the possible cellular responses in vitro.Results:Elevated RPS27L expression, in either feces or tissues, was related to a better prognosis. In vitro, RPS27L-expressing LoVo cells ceased DNA synthesis and apoptotic activity while the expression of their DNA repair molecules was upregulated.Conclusions:Elevated RPS27L may improve the prognoses of certain CRC patients by enhancing the DNA repair capacity of their colonic cells, and can be determined in feces. By integrating clinical, molecular, and cellular data, our study demonstrates that fecal RPS27L may be a useful index for predicting prognoses and guiding personalized therapeutic strategies, especially in patients with intermediate-stage CRC.
AB - Background:The development and progression of colorectal cancer (CRC) involve a complex process of multiple genetic changes. Tumor suppressor p53 is capable of determining the fate of CRC cells. However, the role of a p53-inducible modulator, ribosomal protein S27-like (RPS27L), in CRC is unknown.Methods:Here, the differential expression of RPS27L was examined in the feces and colonic tissues of CRC patients, to explore its possible correlation with patient survival and to investigate the cellular mechanisms underlying their clinical outcomes. Eighty intermediate-stage CRC patients (42 at stage II and 38 at stage III) were divided into two groups according to their fecal RPS27L mRNA levels. The survival probabilities of the groups were estimated using the Kaplan-Meier method. The RPS27L protein in the colonic tissues of stage III patients with different prognoses was further examined immunohistochemically. RPS27L expression in LoVo cells was manipulated to examine the possible cellular responses in vitro.Results:Elevated RPS27L expression, in either feces or tissues, was related to a better prognosis. In vitro, RPS27L-expressing LoVo cells ceased DNA synthesis and apoptotic activity while the expression of their DNA repair molecules was upregulated.Conclusions:Elevated RPS27L may improve the prognoses of certain CRC patients by enhancing the DNA repair capacity of their colonic cells, and can be determined in feces. By integrating clinical, molecular, and cellular data, our study demonstrates that fecal RPS27L may be a useful index for predicting prognoses and guiding personalized therapeutic strategies, especially in patients with intermediate-stage CRC.
UR - http://www.scopus.com/inward/record.url?scp=84879496806&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0067043
DO - 10.1371/journal.pone.0067043
M3 - Article
C2 - 23826192
AN - SCOPUS:84879496806
SN - 1932-6203
VL - 8
JO - PLoS ONE
JF - PLoS ONE
IS - 6
M1 - e67043
ER -
